The transcriptional binding protein NFE-1 (also called GF-1 and Ery-f1) Is thought to play a necessary, but not sufficient, role in the regulation of differentiationrelated gene expression In a subset of hematopoietic lineages (erythroid, megakaryocytlc, and basophil-mast cell). In order to clarify the mechanism which underlies the lineage-specificity of the NFE-1 expression, as well as the relationship between the expression of this factor and growth factor responsiveness, we have evaluated the capacity of erythropoietin ( 
INTRODUCTION
Mature end-cells are generated firom pluripotent stem cells through processes leading to an irreversible commitment of progenitor cells. The hematopoietic and mesenchymal (muscle, adipose tissue, endothelial cells) systems are among the best examples of such processes 1 " 3 . In the hematopoietic system, a self-renewing stem cell generates progenitor cells which, in turn, proliferate and progressively differentiate into mature red and white cells. This process is regulated by a series of growth factors in the following sequence: interleukin 3 (IL-3), granulomacrophagic colony stimulating factor (GM-CSF) and lineage specific growth factors, such as erythropoietin (Epo), macrophage (M)-and granulocyte (G)-CSF. The molecular basis for the commitment of progenitor cells to differentiate into distinct cell types is unknown. Signals delivered by different growth factors might regulate the expression of specific transcription factors, inducing a cascade of effects leading to distinct differentiation pathways; alternatively, the expression of growth factor receptors might itself be regulated by a subset of lineage-specific transcription factors necessary for establishing a specialized pattern of gene transcription. These hypotheses are not mutually exclusive. An experimental analysis of these problems has been hampered by the lack of adequate cell lines. In fact, most of the available hematopoietic cell lines are leukemic and do not respond to hematopoietic growth factors. Furthermore, a comparison of the results obtained from lines with different phenotypes is difficult because of their different genetic backgrounds. On the other hand, although normal progenitor cells can be purified in low numbers 4 -5 , gene expression in these cells can be measured only with the relatively insensitive technique of 'in situ' hybridization; moreover, these homogeneous cell populations give rise to a heterogeneous progeny after only one cell division 6 . We recently obtained 7 -8 from the hematopoietic IL-3-dependent cell line 32D 9 a number of lines with the same genotype immortalized at different stages of the differentiation process; these lines respond to each specific hematopoietic growth factor (Epo, GM-CSF and G-CSF) in a fashion similar to their normal counterpart, proliferating and differentiating along the appropriate lineage. In order to clarify the relationship between growth factor-responsiveness and expression of lineage-specific transcription factors, we studied the expression of the gene encoding the transcription factor NFE-1 10 (also known as GF-1" or Ery-fl 12 ) in these different subclones of 32D. This gene has been reported to be expressed, at the mRNA and/or protein level, in erythroid 10 21 genes, and might represent a 'master' gene regulating part of the differentiation program of these cells. In this paper, we show that mRNA encoding NFE-1 is not only transcribed in basophuVmast cells or in erythroblasts but also, at a lower level, in GM-CSF and G-CSF dependent cells committed to differentiate along the macrophagic and granulocytic pathway. Our data are compatible with the hypothesis that NFE-1 is first activated in an early pluripotential progenitor cell and that restriction of NFE-1 mRNA and functional protein to mature erythroid and mast cells occurs by extinction of NFE-1 gene expression in progressively differentiated granulo-monocytic cells. We discuss the possibility that GM-CSF and G-CSF are responsible for the reported granulo-monocytic extinction of NFE-1.
MATERIALS AND METHODS

CeU lines
The Friend erythroleukemia cell line was maintained by bi-weekly passage in IMDM supplemented with /3-mercaptoethanol and 5 % FBS. The 32D cl3 cell line 9 and its Epo-, GM-CSF-, or G-CSFdependent subclones 7 were maintained by bi-weekly passage in McCoys medium (Gibco) modified as described 22 and supplemented with antibiotics, L-glutamine and pyruvic acid (1 % vol/vol, Gibco Laboratories) and horse serum (10%, vol/vol, Hyclone Laboratories, Logan, UT) and the appropriate growth factor (see below). The cells were periodically tested for the presence of mycoplasma contamination with Mycoplasma T.C.n (Gen-probe, San Diego, CA) and were found to be mycoplasma free.
Growth factors LBRM 3S
23 cell-conditioned medium was the supernatant of a serum-free culture of phytohemagglutinin (PHA)-stimulated cells prepared as described 24 . Pure recombinant murine IL-3 25 and GM-CSF 26 were provided by Dr. J.J. Mermod (Glaxo, Geneva, Switzerland). Pure recombinant human Epo 27 and G-CSF 28 were provided by Drs. J. Egrie and L. Souza (Amgen, Thousand Oaks, California), respectively. Each conditioned medium or growth factor was used at a concentration previously shown to be maximally effective in promoting colony formation by each growth factor dependent subclone of 32D 7 , as well as by purified murine progenitor cells 6 -24 under FBS-deprived conditions. These concentrations were 1% (v/v) for LBRM 33 CM, 4x10-'° M for GM-CSF, 6xlO" 10 M for IL-3, 5x 10" 10 M for G-CSF, or 1.5 U/ml for Epo.
Northern blot and RNA hybridization RNA was prepared by phenol-chlorophorm extraction of acid guanidinium thiocyanate lysates 29 . RNA, dissolved in MOPS buffer (20 mM MOPS, 5 mM EDTA, 5mM sodium acetate, pH 7.0), containing 50% formamide and 1.9 M formaldehyde, was heated at 65°C for 15 min, supplemented with 1 /tg of ethidium bromide and loaded onto 1% agarose gel in MOPS buffer containing 0.66 M formaldehyde. The gel was run at 30 V for 18 hrs. After blotting to nitrocellulose membranes, the hybridization was carried out in 4.7xSSPE, 50% formamide, 0.47xDenhardt, 10% dextran sulphate, 0.1% SDS, 0.34% milk, 180 /tgs/ml salmon sperm DNA, at 42°C for 18 hrs. Washing was down to 0.1 xSSC, 0.1% SDS at 50°C. The filters were subsequently hybridized with a murine NFE-1 probe, mouse /3-globin 30 , myeloperoxidase 31 or actin.
RNAase Protection Experiments
Different fragments of the murine NFE-1 cDNA, obtained by polymerase chain amplification from mRNA of MEL cells, were cloned into the Hindm site of the pGEM7 plasmid. In the experiment shown, a labelled 1462 nt. long antisense RNA probe, spanning nucleotides 940 to 1312 of NFE-1 cDNA 11 , was obtained by transcribing with SP6 polymerase 32 a plasmid linearized by digestion with XmnI (the specific activity of the CTP used was 400 Ci/mmole). After RQ1 DNAase digestion and phenol-chloroform extraction, the probe was ethanolprecipitated and used without further purification. Total RNA from MEL, 32D, 32D subclones and NTH 3T3 fibroblasts was hybridized for 18 hrs to the RNA probe ( = 5x10* cpm) at 41 °C in 30 jils of 80% formamide, 0.4 m NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, and then digested for 30 mins at 30°C in 300 /tls with RNAases A and Tl (40 ftgs/ml and 1 jig/ml, final concentration, respectively), followed by proteinase K digestion and phenol-chlorophorm extraction. Gel electrophoresis was in standard 6% acrylamide, 8 M urea sequencing gels.
Electrophoretic mobility shift assay Nuclear extracts (25-50 /xls) were prepared from 1-2X10 6 cells growing in the log phase according to 33 , in the presence of leupeptin, aprotinin and pepstatin. In vitro binding reactions and electrophoretic runs are as in 1314 .
Piasmids for Cell Transfection
The piasmids used for cell transfection have been already described 34 ; briefly, they consist of a CAT vector (pSVo) 34 driven by the normal or a mutated (-175 TC HPFH) 7-globin promoter 19 . The promoterless pSV o , the SV40 enhancer-driven pSV 2 CAT constructs, and the /3-galactosidase reporter plasmid PCH111 have been described in refs. 34, and 35, respectively.
Cell transfection
Cells (20xl0 6 /ml) were transfected by electroporation (Cell porator, BRL, Bethesda, MD; pulse field strength = 750 v/cm and capacitance = 800 /xF, temp = 4°Q with 10 fig of /3-galactosidase reporter plasmid (pCHin) 35 , and/or 25 /xg of a CAT construct. After 48 hours of incubation at 37°C in fresh culture medium supplemented with growth factors, the cells were harvested, counted, resuspended in lysis buffer (0.25M Tris. HC1 pH 7.8) at a concentration of lC^/lO /J and lysed by repeated cycles of freezing and thawing. CAT activity was measured by 14 C-chloramphenicol butyrylation test 19 - 36 and /3-galactosidase activity according to ref. 35 .
RESULTS
Characterization of the growth factor-dependent subclones of 32D
The 32D cell line and its subclones have been described elsewhere 7 -8 . During the course of this study, we have periodically checked the characteristics of these cells which are most relevant to this paper (Table I) .
32D clone 3 is a basophil/mast cell line maintained in IL-3 (10 units/ml) which clones at low frequency in GM-CSF (1 ng/ml) (1 colony/10 3 cells), Epo (1 unit/ml), or G-CSF (10 3 units/ml) (1 colony/10 4 cells). Therefore, a minority of 32D clone 3 cells may be considered multipotent progenitor cells.
32D Ro is a version of 32D maintained for more than a year in conditioned medium containing IL-3 and GM-CSF 37 . 32D Ro still differentiates into basophil/mast cells in the presence of IL-3 and gives rise to colonies at low frequency (1 colony/10 3 cells) in GM-CSF and G-CSF but has lost the capability to respond to Epo. In the presence of GM-CSF or G-CSF, 32D Ro differentiates into monocytes expressing macl, mac2 and mac3 antigens and M-CSF receptors 38 or into neutrophils expressing myeloperoxidase and lactoferrin 37 -38 , respectively. A minority of 32D Ro cells may be considered as progenitor cells restricted to the mast cell and myelo-monocytic lineage.
32D Epo-1 and Epo-2, 32D GM-1 and 32D GM-2, 32D G-l and 32D G-2 are independently isolated Epo-, GM-CSF or G-CSF-dependent subclones of 32D clone 3. The concentrations of Epo, GM-CSF or G-CSF which induce maximal response from these cell lines are similar to those which induce maximal response from normal progenitors under the same culture conditions 6724 . Epo-dependent cells show typical erythroid markers such as hemoglobin, erythrocyte-specific carbonic anhydrase II and Epo receptors (400 Epo receptors per cell with a Kd of 410 pM, values similar to those obtained for CFU-E 39 ). IL-3-responsive revertants (Epo 1 -1) of the Epo-1 and Epo-2 lines may be selected once again by growing the cells in IL-3.
However, these clones express erythroid, but not mast cell, markers. Conversely, GM-CSF-dependent lines (GM-1 and GM-2) only form colonies in response to GM-CSF or IL-3 but not in the presence of Epo or G-CSF. G-CSF dependent lines (G-l and G-2) only form colonies in response to G-CSF. These cells divide few times in the presence of IL-3 and then die. Morphological and cytochemical analyses of these cell lines show that the GM-CSF-dependent cells have characteristics typical of myeloblasts, while G-CSF-dependent cells more closely resemble myelocytes or neutrophilic metamyelocytes. Therefore, the progenitor cells present in the Epo, GM-CSF and G-CSFdependent subclones of 32D are lineage-restricted.
Presence of NFE-1 mRNA and binding activity in the subclones of 32D To assess the relationship between the expression of tiiis gene and commitment to erythropoiesis, we measured the levels of NFE-1 mRNA in all subclones of 32D (Fig.l) . Northern blot analysis showed a single ) 2.2 Kb band hybridizing to NFE-1 cDNA that is present at relatively high levels not only in mouse erythroleukemia (MEL) cells, in the Epo-1 and Epo-2 lines and also in the parent 32D, but also in GM-1 and GM-2 cells. Based on normalization by hybridization to actin mRNA (not shown) or evaluation of rRNA, the level of NFE-1 mRNA in the subclones of 32D was 10-60% of that observed in MEL cells. In particular, the level of NFE-1 was higher in 32D and Epodependent lines and slightly lower in GM-1, GM-2 and 32D Ro. A very low level of NFE-1 mRNA was also found in the welldifferentiated G-CSF-dependent lines, G-l and G-2, upon overexposure of the same autoradiograph (not shown; but see Fig. 2 ). GM-1 and GM-2 cells, when switched from GM-CSF to IL-3, showed 2-3 fold increased levels of NFE-1 mRNA indicating that GM-CSF may inhibit NFE-1 gene expression (Fig.  la, lanes 6 and 7) . Control experiments (Fig. 1 ) using probes for globin and myeloperoxidase as erythroid and myeloid markers, respectively, and for ubiquitous a-actin mRNA (not shown), demonstrated expression of globin mRNA exclusively in the Epo-1 and Epo-2 lines, and of myeloperoxidase mRNA predominantly in G-l, G-2, GM-1 and 32D Ro cells and at lower levels in GM-2 and 32D cells. Expression of NFE-1 mRNA was also investigated by RNAase analysis; using various fragments Table I . Growth characteristics of the 32D subclones used in this study* . Growth factor responsiveness has been evaluated on the basis of the capacity of the cells to give rise to colonies in semisolid cultures in the presence of pure recombinant growth factor under serum-deprived conditions. The cell phenotype has been determined on the basis of cytochemica] analysis (7) or on the basis of the level of expression of lineage-specific markers (7 and Fig. 1) . A family tree describing the origin and the characteristics of all the lines has been published in ref. 8 . of NFE-1 as riboprobes, we found the expected bands in 32D, Epo, GM and, at a much lower level, G cells (Fig. 2 and data  not shown) . The decreased level of NFE-1 mRNA in GM cells treated with GM-CSF versus IL-3 was also confirmed (Fig. 2,  lanes 8 and 9) . No hybridization was detected with RNA from non-hemopoietic cells such as NIH 3T3 (lane 16).
To assess whether NFE-1 mRNA is translated into protein, we determined the ability of nuclear extracts from the various cell lines to bind in vitro to NFE-1 cognate sequences on appropriate oligonucleotides. Figure 3 shows that binding can be clearly detected with extracts from 32D, Epo-and GM-CSFdependent lines. An oligonucleotide 1314 comprising a sequence of the -y-globin promoter capable of binding either NFE-1 or the ubiquitous OTF-1 factor was used. The NFE-1 band comigrated with that generated with MEL extracts, and was selectively abolished in the presence of a competing unlabelled mouse a-globin promoter oligonucleotide 14 carrying a NFE-1 (Fig. 3B , lanes 5 and 6), but not an OTF-1 binding site; neither the NFE-1 nor the OTF-1 band was competed by an unrelated oligonucleotide from the 7-globin CCAAT box region 14 ( Fig.  3B, lanes 7 and 8) . The ability to bind OTF-1 was used as an internal marker, and allowed us to demonstrate NFE-1 binding in different lines at relative levels roughly consistent with those observed by RNA analysis (that is, higher in Epo and slightly lower in GM and 32D lines). Significantly, growth of GM cells in IL-3, rather than in GM-CSF, correlated with a 2-3 fold higher NFE-l/OTF-1 ratio (Fig. 3C) , as expected from the corresponding mRNA levels of NFE-1. Additionally, 32D Ro had a much lower NFE-1 level when treated with G-CSF than when grown in IL-3 (not shown). A very faint band migrating in the NFE-1 position was also seen in the G-l line (consistent with the very low mRNA levels) but the occurrence of some degradation of these extracts prevented conclusive confirmation of its nature (not shown).
Expression of the erythroid-specific 7-globin promoter in different subclones of the 32D cell line Finally, we evaluated the ability of NFE-1 to support transcriptional activity using erythroid-specific 7-globin promoterdriven chloramphenicol acetyltransferase reporter (CAT) plasmids 19 . It has been reported 18 
-
19 that a nucleotide substitution (-175 T-C) in the 7-globin promoter (which is one mutation leading to Hereditary Persistence of Fetal Hemoglobin (HPFH)), results in erythroid-specific overexpression of a reporter HPFH, relative to the normal 7-globin CAT plasmid; the mutation quantitatively and/or qualitatively improves NFE-1 binding to the promoter, and increased expression is dependent on this effect 14 -18 ' 19 . Using these plasmids, we found (Fig. 4) that expression of the 7-globin promoter and the effect of the mutation were seen only in the Epo-dependent cell lines, whether grown in Epo or IL-3. It is noteworthy that, although the cells with the potential to express an erythroid phenotype have been selected with Epo, the events required for erythroid specific expression are inherited in a dominant fashion by the progeny independently from the growth factor in which they grow. In fact, IL-3-dependent revertants of the Epo-dependent subclones are benzidine-positive and have the capacity to express high levels of CAT activity when driven by the ~1 
DISCUSSION
In this paper, we present evidence that NFE-1 is not only expressed in the subclones of the 32D cell lines with basophil/mast cell (the original 32D cell line) or erythroid (32D Epol) phenotype, but also in subclones with early myelomonocytic (32D GM-1, GM-2) or myelocytic (32D G-l, G-2) phenotype, which depend for growth on GM-CSF or G-CSF, respectively, and which have irreversibly lost the capacity to give rise to erythroid (or mast cell) clones. The gradient of expression found among the different subclones correlated with the lineage, the stage of differentiation, and the growth factor responsiveness of the cell lines (Epo IL-3 2: GM-CSF > G-CSF).
The observation that, among mature blood cells, NFE-1 mRNA or protein can be detected in erythroid, megakaryocytic and mast cells only, led to the hypothesis that the NFE-1 gene may be first activated in a progenitor restricted to the erythroidmegakaryocytic-mast cell lineage 16 -17 . However, our data indicate that NFE-1 is also expressed in cells developing into early granulocytes and monocytes, suggesting that the NFE-1 gene might be first activated in a common progenitor to both the erythroid-megakaryocytic-basophilic and myeloid lineages. These data imply that NFE-1 expression is not sufficient (though it might be necessary) for commitment to the erythroidmegakaryocytic-basophilic lineage.
We propose that following activation in a common progenitor, NFE-1 mRNA and protein are produced in cells developing into a variety of lineages, including the myeloid one. Cells developing into erythroblasts or basophils maintain (or possibly increase) their NFE-1 level; however, as myeloid precursors further differentiate, the expression of NFE-1 progressively declines and, eventually, is extinguished. Thus, the observed lineage-specific expression of NFE-1 could be mediated by selective repression of the previously activated gene, in the course of myeloblast differentiation, rather than by selective and lineage-specific activation of the gene during early phases of the commitment process 1617 . We are aware that this model is based on cell lines which, although non-transformed and with an apparent normal karyotype, might differ significantly from normal hematopoietic cells. We are currently investigating die expression of NFE-1 during the process of normal myeloid differentiation in vitro using the polymerase chain reaction technique. The discrepancy between the previous results and the present conclusions could be explained in several ways; the lack of expression of NFE-1 mRNA in the few mouse (2.12) and human (HL60, U937) myeloid lines 11 - 40 previously studied may reflect the absence, in these leukemic cells, of sufficiently early precursors comparable to those maintaining the GM-CSF-and G-CSF-dependent lines. Alternatively, the differences could be due to the use, in the previous experiments, of the relatively insensitive Northern blot technique, which, in our hands, would detect NFE-1 mRNA only after very long exposure in the Gl, but not in the G2 line; NFE-1 mRNA is, however, readily detected by RNAase protection (Fig. 2) in the same lines. Similarly, NFE-1 mRNA levels may be too low in morphologically recognizable myeloid cells to be detected by 'in situ' hybridization 16 .
We have shown an inverse correlation between levels of NFE-1 mRNA and the ability of the cell to differentiate along the myeloid lineage and to respond to either GM-CSF or G-CSF. We do not know whether decreased expression of NFE-1 mRNA in Gl and G2 cells is simply concurrent with differentiation or causally related to G-CSF treatment. Interestingly, the level of NFE-1 expression was regulated to some extent by switching the cells from one factor to another. In particular, the level of NFE-1 increased in 32D GM when switched from GM-CSF to IL-3, and decreased in 32D Ro, switched from IL-3 to GM-CSF or G-CSF. Since a potential NFE-1 binding site is present in the promoter of die erythropoietin-receptor gene, the down-regulation of NFE-1 observed in differentiating GM-CSF-and G-CSFdependent myeloid cells might prevent the expression, in more mature cells, of a receptor (such as die Epo's), which is inappropriate to granulocytic differentiation. To test this hypothesis, we measured the level of Epo-receptor mRNA in the different 32D subclones (manuscript in preparation). In effect, the gradient of Epo receptor-mRNA expression found among the different lines correlates very well with the gradient of NFE-1 expression (Epo-receptor mRNA level being the highest in the Epo-dependent and in the original 32D cell line, detectable but low in die GM-CSF dependent but Epo unresponsive GM1 and GM2 lines, and undetectable in die G-CSF dependent lines). These results delineate a network of interactions between growth factor receptors and transcription factors which might be relevant to our understanding of the molecular basis for hematopoietic differentiation.
It is not clear whedier NFE-1 plays any role in die early myeloid cells in which it is expressed; as NFE-1 regulates several genes in both erythroid and megakaryocytic cells, it is tempting to speculate that NFE-1 might also control a subset of genes expressed in early myeloid cells. This subset could be represented either by genes expressed in all hematopoietic lineages or by genes specific for myeloid cells.
Finally, although NFE-1 is the only known tissue-specific DNA binding protein able to interact widi and activate die 7-globin promoter 141819 , the mere presence of NFE-1 is insufficient to activate eidier endogenous globin gene expression (as previously shown 16 -17 ), or even exogenous globin transcription (as assayed using NFE-1-dependent 7-globin promoters) (Fig. 4) . Since NFE-1 from cells such as 32D and GM, which show little or no expression of die transfected 7-globin promoter, is able to bind 7-globin promoter oligonucleotides containing its cognate site (Fig. 3) , it is possible that repression of negatively acting factors is needed to activate the 7-globin promoter in these cells. This point emphasizes the importance of the previous developmental history of cells for specific gene expression, in agreement with recent data on myo-D-induced muscle cell differentiation 41 . Alternatively, in order to provide its transcriptional activation function, NFE-1 may require posttranslational modifications in cells expressing globin genes.
After submitting this paper, we learned that Perkins et al. 42 reported me presence of very low amounts of a NFE1 -like binding activity in several non-erythroid cells, including Hela. However, since mRNA protection studies were not reported, it is not yet clear whether the binding activity reported in uiis study is due to NFE-1 protein, or to odier related proteins such as those recendy detected in several laboratories.
